See more : Gold Hydrogen Limited (GHY.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Invitae Corporation (NVTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invitae Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- PTT Oil and Retail Business Public Company Limited (OR.BK) Income Statement Analysis – Financial Results
- Reneo Pharmaceuticals, Inc. (RPHM) Income Statement Analysis – Financial Results
- Makkah Construction & Development Company (4100.SR) Income Statement Analysis – Financial Results
- CRH plc (CRH) Income Statement Analysis – Financial Results
- Qingdao Tianneng Heavy Industries Co.,Ltd (300569.SZ) Income Statement Analysis – Financial Results
Invitae Corporation (NVTA)
About Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516.30M | 460.45M | 279.60M | 216.82M | 147.70M | 68.22M | 25.05M | 8.38M | 1.60M | 148.00K | 0.00 |
| Cost of Revenue | 417.26M | 348.67M | 198.28M | 118.10M | 80.11M | 50.14M | 27.88M | 16.52M | 5.62M | 667.00K | 0.00 |
| Gross Profit | 99.05M | 111.78M | 81.32M | 98.72M | 67.59M | 18.08M | -2.83M | -8.15M | -4.02M | -519.00K | 0.00 |
| Gross Profit Ratio | 19.18% | 24.28% | 29.09% | 45.53% | 45.76% | 26.50% | -11.30% | -97.22% | -250.62% | -350.68% | 0.00% |
| Research & Development | 402.09M | 416.09M | 240.61M | 141.53M | 63.50M | 46.47M | 44.63M | 42.81M | 22.14M | 16.04M | 5.56M |
| General & Administrative | 192.31M | 248.07M | 324.57M | 79.07M | 52.23M | 39.47M | 24.09M | 16.05M | 12.61M | 5.76M | 3.00M |
| Selling & Marketing | 218.88M | 225.91M | 168.32M | 122.24M | 74.43M | 53.42M | 28.64M | 22.48M | 8.76M | 2.43M | 0.00 |
| SG&A | 411.20M | 473.98M | 492.89M | 201.31M | 126.66M | 92.89M | 52.72M | 38.53M | 21.37M | 8.20M | 3.00M |
| Other Expenses | 8.05M | 25.68M | -32.33M | -3.89M | -2.57M | -303.00K | 348.00K | -94.00K | -79.00K | -26.00K | 2.00K |
| Operating Expenses | 813.28M | 890.07M | 733.50M | 342.83M | 190.15M | 139.36M | 97.35M | 81.33M | 43.51M | 24.23M | 8.56M |
| Cost & Expenses | 1.23B | 1.24B | 931.77M | 460.94M | 270.26M | 189.50M | 125.23M | 97.86M | 49.13M | 24.90M | 8.56M |
| Interest Income | 56.75M | 49.90M | 29.77M | 12.41M | 0.00 | 0.00 | 0.00 | 211.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 56.75M | 49.90M | 29.77M | 12.41M | 7.03M | 3.65M | 421.00K | 0.00 | 61.00K | 59.00K | 43.00K |
| Depreciation & Amortization | 150.13M | 106.15M | 6.72M | 12.32M | 13.54M | 9.18M | 6.55M | 5.32M | 2.32M | 928.00K | 277.00K |
| EBITDA | -3.12B | -391.64M | -652.17M | -244.11M | -111.59M | -121.58M | -93.63M | -89.48M | -45.19M | -23.85M | -8.28M |
| EBITDA Ratio | -109.26% | -145.97% | -230.85% | -106.91% | -75.55% | -178.22% | -398.57% | -1,068.00% | -2,968.02% | -16,115.54% | 0.00% |
| Operating Income | -714.24M | -778.29M | -652.17M | -244.11M | -122.56M | -121.28M | -100.18M | -89.48M | -47.53M | -24.75M | -8.56M |
| Operating Income Ratio | -138.34% | -169.03% | -233.25% | -112.59% | -82.98% | -177.77% | -399.96% | -1,068.00% | -2,963.09% | -16,725.00% | 0.00% |
| Total Other Income/Expenses | -2.44B | 362.42M | -62.10M | -16.30M | -9.60M | -3.96M | -73.00K | -305.00K | 36.00K | -85.00K | -41.00K |
| Income Before Tax | -3.15B | -415.86M | -714.27M | -260.42M | -132.16M | -125.24M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Income Before Tax Ratio | -610.34% | -90.32% | -255.46% | -120.10% | -89.48% | -183.57% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| Income Tax Expense | -44.90M | -36.86M | -105.40M | -18.45M | -2.80M | -1.86M | -5.78M | -5.11M | -2.33M | 33.00K | 45.00K |
| Net Income | -3.11B | -379.01M | -608.87M | -241.97M | -129.36M | -123.38M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Net Income Ratio | -601.64% | -82.31% | -217.77% | -111.60% | -87.58% | -180.85% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| EPS | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| EPS Diluted | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| Weighted Avg Shares Out | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
| Weighted Avg Shares Out (Dil) | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
Labcorp Finalizes Acquisition of Select Assets of Invitae
Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of...
Labcorp Announces 2024 Second Quarter Results
Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year...
Invitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy Patients
– Program provides accessible and affordable testing for pediatric epilepsy patients – – Genetic and clinical insights from test results to strengthen Invitae's rare disease database – SAN FRANCISCO , July 22, 2024 /PRNewswire/ -- Invitae (OTC: NVTAQ), a leading...
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
Laboratory service provider Labcorp said on Wednesday it will acquire Softbank-backed Invitae Corp's assets auctioned through a voluntary bankruptcy protection process, a few months after the genetic test maker filed for bankruptcy.
Labcorp Announces Winning Bid for Select Assets of Invitae
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C. , April 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a...
Invitae Enters into Agreement with Labcorp for Sale of Business
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees –...
Invitae Publishes its Environmental, Social and Governance (ESG) Report
– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO , April 22, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented...
Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
– An Invitae-developed innovative approach to help reduce variants of uncertain significance – SAN FRANCISCO , March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with...
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
SAN FRANCISCO , March 6, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit and cash burn. Estimated unaudited financial results for fourth quarter 2023 Fourth...
Source: https://incomestatements.info
Category: Stock Reports